Company Overview and News
2018-09-04 seekingalpha - 1
Mason Hawkins’ 13F portfolio value increased ~10% from $8.17B to $8.95B this quarter. The number of positions remained steady at 28.
SAH CEIX.WI SONC CMCSK SHL CABO BAMGF GE CNX.WI INFY UTX MAT GHC ATU SKHCF GOOGL RLGY INFY BAMKF BATRA PK LSXMB BATRK HCMLY CCV LSXMA CTL BATRR CCZ GOOG LLPFX SKHCY AGN AMR BEN BATRB BEL BIDU BAM CEIX VIPS GEC FWONB CMCSA SOFO FDX FWONA VSAT HCMLF CCV.CL FWONK GNE LSXMK SIMA CNX
2018-08-19 seekingalpha - 4
SQ Advisors has just eleven positions. The top three holdings are CarMax, Allison Transmission, and Brookfield Asset Management, and they add up to ~36% of the entire portfolio.
KMX LBTY HXL ALSN CAXPF TYLE CHTR LBTYK TYL LILAB AAPL BAM LBRDB CABO BAMGF BBU LBTYB AXTA LBTYA LBRDK BRK.A SCHW HXL LILAK LBRDA SBAC BAMKF LILA
Good morning, and welcome to the Cable One's Second Quarter 2018 Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded.
Cable One (CABO - Free Report) came out with quarterly earnings of $7.65 per share, missing the Zacks Consensus Estimate of $7.97 per share. This compares to earnings of $4.97 per share a year ago. These figures are adjusted for non-recurring items.
CABO HCCDZ HCHC GWRS UCTI SND RLH UCTT
2018-08-04 seekingalpha - 4
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
SYY AMAL RUTH BECN QES WHR HABT VIAB STI-A TSN WING SNAP MRCY WHD JCOM NWSA GPRE CRSP MDT REV GPK ZOES VCTR MGM WSO DFRG CTB OLED RAD GMVHF TEN HMI FLBD AGN CL AAPL UCBI KO USAP CBS GJV RRGB MUSA MCHP DDD "QES" VC TSLA CAKE APTV VPG BYD ARHVF EAT XON AMRS BLMN LDOS CVS UAL AMZN AIT NDSN CABO UPS KDP AAL CARS BR STE MAR REVG STI CLX BKEP TXRH DAN PG YELP TREC CDLX STMP ANDV MAR.WI MYL TSNU NWS KWR GM DIN FRPT DIS ECL F M FDX K BMI TGT ZG BKNG EOLS THRM DPZ ORLY
Investors interested in stocks from the Cable Television sector have probably already heard of Comcast (CMCSA - Free Report) and Cable One (CABO - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
I previously posted two articles on Comcast (NASDAQ:CMCSA) arguing that the stock was cheap. I promised a “Part III” discussing Comcast’s strategy (and its place in the new media world) beyond financials and valuation covered in the first two parts. The potential acquisitions of Twenty-First Century Fox Inc (NASDAQ:FOXA) businesses and Sky, Plc (OTCQX:SKYAY) delayed Part III because the strategy of the combined company would be different based on which assets they landed.
CABO FOX CMCSA FOXA
Good afternoon. Welcome to Clearfield’s Fiscal Third Quarter 2018 Earnings Conference Call. My name is Ariel, and I will be your operator this afternoon. Joining us for today’s presentation are the company’s President and CEO, Cheri Beranek; and CFO, Dan Herzog. Following their commentary, we will open the call for questions.
Shaw Communications Inc. (SJR - Free Report) reported third-quarter fiscal 2018 adjusted earnings from continuing operations of 32 cents per share, beating the Zacks Consensus Estimate by a nickel. Including impairment (related to the company’s investment in Corus Entertainment) and restructuring charges of C$297 million, the company reported loss of C$91 million. The company incurred charges of C$13 million related to Total Business Transformation (“TBT”) initiative and Voluntary Departure Program (“VDP”) restructuring programs.
CABO CJREF SJR.B CJR.B AAPL SJR SJRWF PII WMT SJR.A
DISH Network (DISH - Free Report) is expanding integration with Amazon (AMZN - Free Report) voice assistant Alexa. The company recently added new Alexa voice control capabilities to its set-top boxes — Hopper, Hopper Duo, Joey and Wally. The latest integration will now allow DISH users to not only play or pause but also to navigate, fast-forward, rewind and search content based on channel, title, actor or genre.
CABO DISH NFLX
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to CABO / Cable One Inc. on message board site Silicon Investor.
as of ET